Provider perspectives on the importance of education patients about potential adverse events they may experience when initiating treatment with FGFR inhibitors.
Retrospective analysis of patients with myelodysplastic syndromes showed trends in treatment patterns that suggest: improved trend persistence with oral decitabine and cedazuridine versus intravenous/subcutaneous hypomethylating agents beyond 6 months comparable persistence between oral decitabine and cedazuridine and intravenous/subcutaneous hypomethylating agents at early stages of therapy PRINCETON, N.J., Dec. 10, 2023 /PRNewswire/ — Taiho Oncology, Inc. announced […]
Taiho Oncology Announces Presentation of Data From a U S Real-Word Study of Oral Decitabine and Cedazuridine streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.